MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

Search

Pacira Pharmaceuticals Inc-DE

Cerrado

SectorSalud

24.87 3.37

Resumen

Variación precio

24h

Actual

Mínimo

23.56

Máximo

24.89

Métricas clave

By Trading Economics

Ingresos

160M

16M

Ventas

19M

187M

P/B

Media del Sector

11.23

63.778

BPA

0.91

Margen de beneficio

8.566

Empleados

788

EBITDA

165M

51M

Recomendaciones

By TipRanks

Recomendaciones

Neutral

Estimación a 12 meses

+36.39% upside

Dividendos

By Dow Jones

Próximas Ganancias

6 may 2025

Estadísticas de Mercado

By TradingEconomics

Capitalización de Mercado

-72M

1.2B

Apertura anterior

21.5

Cierre anterior

24.87

Noticias sobre sentimiento de mercado

By Acuity

21%

79%

47 / 386 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Weak Bullish Evidence

Pacira Pharmaceuticals Inc-DE Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

2 jul 2024, 16:22 UTC

Principales Movimientos del Mercado

Pacira BioSciences Shares Tumble as FDA Approves Exparel Generic

Comparación entre iguales

Cambio de precio

Pacira Pharmaceuticals Inc-DE Esperado

Precio Objetivo

By TipRanks

36.39% repunte

Estimación a 12 meses

Media 32.83 USD  36.39%

Máximo 50 USD

Mínimo 21 USD

De acuerdo con 8 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Pacira Pharmaceuticals Inc-DE Dist en los últimos 3 meses.

Consenso

By TipRanks

Neutral

8 ratings

3

Comprar

4

Mantener

1

Vender

Puntuación técnica

By Trading Central

23.67 / 24.37Soporte y Resistencia

Corto Plazo

Weak Bullish Evidence

Medio plazo

Bearish Evidence

Largo Plazo

Bullish Evidence

Sentimiento

By Acuity

47 / 386 Clasificación en Salud

Noticias sobre sentimiento de mercado

Coyuntura alcista notoria

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por debajo de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Pacira Pharmaceuticals Inc-DE

Pacira BioSciences, Inc. engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature to targeted nerves. It has a development and commercialization, and supply agreement with Aratana Therapeutics, Inc. for NOCITA, a bupivacaine liposome injectable suspension product. The company was formerly known as Pacira Pharmaceuticals, Inc. and changed its name to Pacira BioSciences, Inc. in April 2019. Pacira BioSciences, Inc. was incorporated in 2006 and is headquartered in Tampa, Florida.